

STRICTLY PRIVATE AND CONFIDENTIAL

28 January 2025

China NT Pharma Group Company Limited Suite 3613, 36/F Cosco Tower 183 Queen's Road Central Hong Kong Attention: the Board of Directors

Ref: 2024-006

Dear Sirs,

Re: China NT Pharma Group Company Limited (the "Company")

- (i) Connected Transaction in relation to Loan Capitalization involving Subscription of Shares under Specific Mandates; and
- (ii) Application for the Whitewash Waiver (collectively, the "Transactions")

We refer to circular issued by the Company dated 28 January 2025 (the "Circular") in relation to the Transactions. Terms used in this letter shall have the same meanings as given to them under the definitions section of the Circular.

We hereby give and have not withdrawn our written consent to the issue of the Circular with the inclusion of our letter of advice dated 28 January 2025 in respect of the Transactions and our report on the Profit Estimate dated 28 January 2025 and references to our name, in the form and context in which it appears. We hereby further consent to this letter being made available for public inspection as described in the section headed "16. Documents on Display" in Appendix II to the Circular.

As at the Latest Practicable Date, we did not have any direct or indirect shareholding in any member of the Group, or any right to subscribe for or to nominate persons to subscribe for securities in any member of the Group, or any interests, directly or indirectly, in any asset which had been acquired, disposed of by or leased to any member of the Group, or was proposed to be acquired, disposed of by or leased to any member of the Group, since 31 December 2023, being the date to which the latest published audited financial statements of the Group were made up.

General Line: (852) 3665 8111 Fax: (852) 2559 2880, 2559 7800



Yours faithfully, For and on behalf of

Astrum Capital Management Limited

Hidulf Kwan

Managing Director

General Line: (852) 3665 8111 Fax: (852) 2559 2880, 2559 7800